You just read:

First Human Subject Enrolled in Lumosa Therapeutics' Phase 1 Trial for LT3001, a New Drug Molecule for Acute Ischemic Stroke

News provided by

Lumosa Therapeutics

Jul 31, 2017, 21:46 ET